Aortic valve stenosis in 2026: from emerging mechanisms to clinical drug development.

doi:10.1016/j.atherosclerosis.2026.121865

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Aortic valve stenosis in 2026: from emerging mechanisms to clinical drug development.

Atherosclerosis - 1 Sept 2026

Zheng Kang H, Gaillard Emilie L, Kroon Jeffrey, Stroes Erik S G, Boekholdt S Matthijs

Abstract excerpt

Calcific aortic valve stenosis (AS) is the most prevalent valvular heart disease in high-income countries, affecting 9.4 million persons globally. While surgical and transcatheter aortic valve replacement have transformed outcomes, they address end-stage disease rather than the underlying pathobiology. The development of pharmacological therapies to slow or halt AS progression would represent a paradigm shift in...

Topics

Join the communities discussing this publication.

Aortic Valve
Aortic Valve Stenosis
Calcinosis
Cardiovascular Agents
Drug Development
Genome-Wide Association Study
Lipoprotein(a)

Source

Open in PubMed

Identifiers

PMID: 42580147
DOI: 10.1016/j.atherosclerosis.2026.121865

Genes

LPA
PCSK9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Risk Factors